434 related articles for article (PubMed ID: 17725846)
1. Developing paediatric medicines: identifying the needs and recognizing the challenges.
Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
[TBL] [Abstract][Full Text] [Related]
2. Development of medicines for children in Europe: ethical implications.
Saint Raymond A; Brasseur D
Paediatr Respir Rev; 2005 Mar; 6(1):45-51. PubMed ID: 15698816
[TBL] [Abstract][Full Text] [Related]
3. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
4. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
5. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
6. European perspectives on pediatric formulations.
Breitkreutz J
Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
[TBL] [Abstract][Full Text] [Related]
7. [Are children getting the right drugs?].
Bratlid D
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
[TBL] [Abstract][Full Text] [Related]
8. Changing requirements for evaluation of pharmacologic agents.
Chesney RW; Christensen ML
Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
[TBL] [Abstract][Full Text] [Related]
9. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
10. Ethical issues of clinical trials in children: a European perspective.
Sammons H
Arch Dis Child; 2009 Jun; 94(6):474-7. PubMed ID: 19208673
[TBL] [Abstract][Full Text] [Related]
11. [Determination of drug posology in pediatrics].
Autret E; Vasmant D
Therapie; 1995; 50(4):381-6. PubMed ID: 7482393
[TBL] [Abstract][Full Text] [Related]
12. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
13. Paediatric drug development.
Schachter AD; Ramoni MF
Nat Rev Drug Discov; 2007 Jun; 6(6):429-30. PubMed ID: 17633788
[No Abstract] [Full Text] [Related]
14. Pediatric clinical trial experience: government, child, parent and physician's perspective.
Salazar JC
Pediatr Infect Dis J; 2003 Dec; 22(12):1124-7. PubMed ID: 14688585
[TBL] [Abstract][Full Text] [Related]
15. Evidence used for approval of new drugs.
Botstein P
Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
[TBL] [Abstract][Full Text] [Related]
16. The European Regulation on medicines for paediatric use.
Dunne J
Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance.
Vlahović-Palčevski V; Mentzer D
Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
[TBL] [Abstract][Full Text] [Related]
18. Global aspects of drug development.
Hoppu K; Hogerzeil HV
Handb Exp Pharmacol; 2011; 205():353-72. PubMed ID: 21882121
[TBL] [Abstract][Full Text] [Related]
19. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
20. European paediatric research and children's therapeutic needs. A trial review.
Pandolfini C; Bonati M
Acta Paediatr; 2008 Sep; 97(9):1232-7. PubMed ID: 18489618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
